Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.122.026791 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Huilin Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy University of Florida College of Pharmacy Gainesville FL USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Hispanic populations are more likely to develop diabetes and its related diseases than non‐Hispanic White populations. Little evidence exists to support whether the cardiovascular and renal benefits of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonists are generalizable to the Hispanic populations. Methods and Results We included the cardiovascular and renal outcome trials (up to March 2021) that reported the major adverse cardiovascular events (MACEs), cardiovascular death/hospitalization for heart failure, and composite renal outcomes by ethnicity in individuals with type 2 diabetes (T2D), calculated pooled hazard ratios (HRs) with 95% CIs using fixed‐effects models, and tested the differences between Hispanic and non‐Hispanic populations ( P for interaction [ P interaction ]). In 3 sodium‐glucose cotransporter 2 inhibitor trials, there was a statistically significant difference between Hispanic (HR, 0.70 [95% CI, 0.54–0.91]) and non‐Hispanic (HR, 0.96 [95% CI, 0.86–1.07]) groups in treatment effects on MACE risk ( P interaction =0.03), except for risks of cardiovascular death/hospitalization for heart failure ( P interaction =0.46) and composite renal outcome ( P interaction =0.31). In 5 glucagon‐like peptide‐1 receptor agonist trials, there was no statistically significant difference in treatment effect on MACE risk between Hispanic (HR, 0.82 [95% CI, 0.70–0.96]) and non‐Hispanic (HR, 0.92 [95% CI, 0.84–1.00]) populations ( P interaction =0.22). In 3 dipeptidyl peptidase‐4 inhibitor trials, the HR for MACE risk appeared greater in Hispanic (HR, 1.15 [95% CI, 0.98–1.35]) than non‐Hispanic (HR, 0.96 [95% CI, 0.88–1.04]) populations ( P interaction =0.045).
Conclusions
Compared with non‐Hispanic individuals, Hispanic individuals with T2D appeared to obtain a greater benefit of lowered MACE risk with sodium‐glucose cotransporter 2 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Outcomes and Policy University of Florida College of Pharmacy Gainesville FL USA.
- Department of Health Outcomes and Biomedical Informatics College of Medicine, University of Florida Gainesville FL USA.
- Department of Family, Youth and Community Sciences Institute of Food and Agricultural Sciences, University of Florida Gainesville FL USA.
- Department of Neurology Medical University of South Carolina Charleston SC USA.
- Division of Endocrinology Department of Pediatrics University of Florida College of Medicine Gainesville FL USA.
- Center for Drug Evaluation and Safety University of Florida Gainesville FL USA.
ORCID-Profile: Huilin Tang, Weihan Chen, Jiang Bian, Daniel T Lackland, Desmond A Schatz, Jingchuan Guo
Förderung
- NIDDK NIH HHS
Zitieren
APA
Tang, H., Chen, W., Bian, J., O'Neal, L. J., Lackland, D. T., Schatz, D. A., & Guo, J. (2023). Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.026791
Vancouver
Tang H, Chen W, Bian J, O'Neal LJ, Lackland DT, Schatz DA, et al. Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.026791
BibTeX
@article{Tang2023,
author = {Tang, Huilin and Chen, Weihan and Bian, Jiang and O'Neal, LaToya J and Lackland, Daniel T and Schatz, Desmond A and Guo, Jingchuan},
title = {Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.122.026791}
}
EUVIMED